Osimertinib in first line setting: preventive or delayed T790M occurrence?

The FLAURA clinical trial conducted by Soria et al. are recently reported in the New England Journal of Medicine, this trail was designed to test the efficacy of Osimertinib as first-line treatment for none-small-cell lung cancer (NSCLC) patients. 556 previously untreated advanced NSCLC patients with EGFR mutation-positive (exon 19 deletion or L858R) are enrolled and 279 of which are assigned to the Osimertinib group.